Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHRQ on heart disease treatments

This article was originally published in The Gray Sheet

Executive Summary

Long-term freedom from chest pain and repeat revascularization is significantly greater with coronary artery bypass surgery than angioplasty, but CABG causes significantly more post-procedure strokes, the Agency for Healthcare Research and Quality concludes in a comparative-effectiveness literature 1review finalized Oct. 15. Overall survival rates were similar. The AHRQ review included analysis of 23 randomized controlled trials comparing percutaneous coronary intervention to CABG. The report, released in draft form in January, says there is not enough data to assess comparative effectiveness in specific patient subgroups and that more study results are needed to assess the impact of stents, and drug-eluting stents in particular, on outcomes (2"The Gray Sheet" Jan. 29, 2007, p. 16)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025379

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel